Skip to main content
Fig. 1 | AIDS Research and Therapy

Fig. 1

From: Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial

Fig. 1

The graph shows the mean change in lithium concentrations. The bars indicate median and interquartile range change in lithium concentrations over the 24 weeks in the lithium and placebo arms respectively. Sham lithium concentrations were generated for the placebo arm. The broken line indicates the target therapeutic range of 0.6–1.0 mmol/L

Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us